A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products

Enrolling by invitation

Conditions studied: Solid Tumor Cancer, Solid Tumor, Unspecified, Adult, Colorectal Carcinoma, Colorectal Carcinoma (CRC), Non Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Pancreatic Cancer, NSCLC, Mesothelioma, Ovarian Cancer, Ovarian Carcinoma, Head and Neck (HNSCC), Head and Neck Cancer, Renal Cell Carcinoma (Kidney Cancer), Triple Negative Breast Cancer (TNBC)

In brief

This protocol is to ensure consistent long-term follow-up for delayed safety events in participants who received A2 Bio gene therapy (GT) products.

Key facts

Study ID

NCT06885424

Run by

A2 Biotherapeutics Inc.

People needed

400

Starts

2025-07-31

Expected to finish

2040-03-31

Last updated by the study team

2026-05-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Received any amount of A2 Bio GT product on a previous A2 Bio interventional study
• Able to provide written informed consent for this long-term follow-up study
• Able to comply with study requirements

You may not qualify if…

• There are no specific exclusion criteria for this study

Where it is running

• Banner Health — Gilbert, Arizona, United States
• Mayo Clinic — Rochester, Minnesota, United States
• NYU Langone Medical Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.